103429-32-9 Usage
Uses
Used in Pharmaceutical Industry:
CTAP is used as a μ-opioid receptor antagonist for the regulation of aggressive behavior in mammals. It targets the central nucleus of the amygdala, which is responsible for controlling sodium appetite and regulating sodium intake.
Used in Pain Management:
CTAP is used as a μ-opioid receptor antagonist to study the anti-hyperalgesic effect of dipeptidyl peptidase 4 (DPP4) inhibitor isoleucine-proline-isoleucine (IPI) and vildagliptin in carrageenan-induced inflammation. This application helps in understanding the role of MOR in pain management and the potential of CTAP in treating pain-related conditions.
Used in Neurological Research:
CTAP is used as a μ-opioid receptor antagonist to study the role of MOR in glutamate and gamma-aminobutyric acid (GABA) efflux during predator stress in rats. This research contributes to the understanding of the neurochemical mechanisms underlying stress responses and the potential therapeutic applications of CTAP in stress-related disorders.
Used in Endogenous Opioid Peptide Research:
CTAP is used as a μ-opioid receptor antagonist to determine the endogenous opioid peptide involved in blocking pain induced by activated gastrin-releasing peptide (Grp+) neurons. This application aids in the identification of specific endogenous opioid peptides and their roles in pain modulation, potentially leading to the development of novel pain management strategies.
Biochem/physiol Actions
CTAP is a peptide antagonist produced from somatostatin analogs.
Check Digit Verification of cas no
The CAS Registry Mumber 103429-32-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,3,4,2 and 9 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 103429-32:
(8*1)+(7*0)+(6*3)+(5*4)+(4*2)+(3*9)+(2*3)+(1*2)=89
89 % 10 = 9
So 103429-32-9 is a valid CAS Registry Number.
103429-32-9Relevant academic research and scientific papers
Opiate aromatic pharmacophore structure-activity relationships in CTAP analogues determined by topographical bias, two-dimensional NMR, and biological activity assays
Bonner, G. Gregg,Davis, Peg,Stropova, Dagmar,Edsall, Sidney,Yamamura, Henry I.,Porreca, Frank,Hruby, Victor J.
, p. 569 - 580 (2007/10/03)
Topographically constrained analogues of the highly μ-opioid-receptor- selective antagonist CTAP (H-D-Phe-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2, 1) were prepared by solid-phase peptide synthesis. Replacement of the D-Phe residue with conformatio
Design and Synthesis of Conformationally Constrained Somatostatin Analogues with High Potency and Specificity for μ Opioid Receptors
Pelton, John T.,Kazmierski, Wieslaw,Gulya, Karoly,Yamamura, Henry I.,Hruby, Victor J.
, p. 2370 - 2375 (2007/10/02)
A series of cyclic, conformationally constrained peptides related to somatostatin were designed and synthesized in an effort to develop highly selective and potent peptides for the μ opioid receptor.The following new peptides were prepared and tested for
